Table 2.
Circulating cells and inflammatory markers.
| Cell counts | Without SVD progression | SVD progression | Incident lesions |
|---|---|---|---|
| WBC, 106/ml | 5.2 (4.7–6.7) | 6.2 (5.1–7.3) | 7.0 (4.8–7.7) |
| Neutrophils, 106/ml | 2.9 (2.3–3.6) | 3.2 (2.5–4.5) | 4.2 (2.6–5.0) |
| Lymphocytes, 106/ml | 1.8 (1.3–2.2) | 2.0 (1.5–2.3) | 1.9 (1.6–2.1) |
| Monocytes, 106/ml | 0.5 (0.4–0.7) | 0.6 (0.4–0.7) | 0.6 (0.3–0.7) |
| Monocytes, % | 8.8 (7.5–11.0) | 8.8 (7.4–10.5) | 7.8 (6.7–9.8) |
| Classical monocytes, % gated | 82.5 (78.0–88.0)a | 80.2 (75.1–88.2) | 79.6 (73.7–87.1) |
| Intermediate monocytes, % gated | 7.9 (4.8–14.1)a | 8.3 (4.5–11.9) | 5.6 (2.5–11.7) |
| Nonclassical monocytes, % gated | 7.0 (5.0–10.0)a | 5.8 (4.5–12.5) | 11.7 (5.4–13.2) |
| Circulating inflammatory markers | |||
| hsCRP, pg/ml | 1.4 (0.5–4.1) | 1.1 (0.8–5.3) | 1.3 (0.9–12.3) |
| hsIL-6, pg/ml | 5.7 (3.3–9.6) | 6.6 (4.0–11.4)a | 5.1 (3.2–9.2)a |
| E-selectin, pg/ml | 13.9 (10.7–17.5) | 19.4 (16.8–24.3)* | 20.0 (19.3–27.2)* |
| VCAM-1, pg/ml | 392 (333–458) | 410 (344–471) | 424 (345–527) |
| MMP-2, pg/ml | 898 (817–959)a | 954 (863–1058) | 968 (823–1,082) |
| CCL2, pg/mlb | 31.2 (31.2–74.1) | 36.8 (31.2–238) | 43.5 (31.2–370) |
Participants without SVD progression (n = 22), SVD progression (n = 13), incident lesions (n = 7). Median (IQR). P-values are corrected for age, sex, and hypertension with ANCOVA.
*
P < 0.05.
a
Data are missing for one participant.
b
Concentrations of CCL2 were often below the limit of detection of 31.2 pg/ml.
CRP, C-reactive protein; IL, interleukin; IQR, interquartile range; MMP, matrix metalloproteinase; SVD, small vessel disease; VCAM, vascular cell adhesion molecule; WBC, white blood cell. The bold values are statistically significant.